Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
An ideal climate with Powerful units K48UXR-727P
Contact Us● Powerful units with high cooling and heating capacity
● Lightweight design, intelligent design
● Longer battery life, meeting the need for a full night’s sleep
● Energy saving/lightweight/quiet
● Split structure, bottom mounted
● Energy saving and low consumption, quality assurance
● The company has passed the automotive industry IATF16949 certification -
Jinko Tiger Neo N Type Solar Panel 605W 615W 625W
Contact UsModel NO:78HL4-BDV 605-625 Watt
Cell Type: N-type Mono-crystalline
Weight:34.6 kg
Transport Package:Wooden Pallet and Carton Packing
Specification:2465*1134*30mm
Trademark:Jinko solar
Origin:China -
The Latest 5-in-1 Car Jump Starter and Tire Inflator
Contact UsThis innovative device combines four essential functions in one compact unit, ensuring you’re well-equipped for any roadside emergency or outdoor adventure.
-
Prune/Plum Powder Extract
Contact UsPlums are delicious and nutritious fruits that offer a variety of health benefits. They are rich in vitamins, minerals, antioxidants, and dietary fiber. Here are some of the key health benefits associ
Reviews
There are no reviews yet.